American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
about
Erythropoiesis-stimulating agents for myelodysplastic syndromesErythropoiesis-stimulating agents for myelodysplastic syndromesHematopoietic growth factors: personalization of risks and benefitsPhysiology and pharmacology of erythropoietinPrevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. ironIron deficiency in gastrointestinal oncologyA low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic diseaseAnemia in the elderly: a consequence of aging?Stem-cell-based, tissue engineered tracheal replacement in a child: a 2-year follow-up study.A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.Cost-effectiveness of continuous erythropoietin receptor activator in anemia.Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan databasePredictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998-2003)Evaluation and management of anemia in the elderlyThe effects of erythropoietin dose titration during high-fat diet-induced obesity.Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in ratsHerpesvirus entry mediator regulates hypoxia-inducible factor-1α and erythropoiesis in mice.Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusionsEmerging EPO and EPO receptor regulators and signal transducers.Iron metabolism and iron supplementation in cancer patientsClinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemiaErythropoietin: multiple targets, actions, and modifying influences for biological and clinical considerationThe role of intravenous iron in the treatment of anemia in cancer patientsThe mechanisms of chansu in inducing efficient apoptosis in colon cancer cells.Iron in multiple myeloma.Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss.Comparison of the effects of erythropoietin and anakinra on functional recovery and gene expression in a traumatic brain injury model.Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.Quality of life and supportive care in multiple myeloma.Iron deficiency in cancer patients.Guidelines for supportive care in multiple myeloma 2011.Diagnosis and management of anaemia of chronic disease: current status.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.Activin receptor antagonists for cancer-related anemia and bone disease.Contemporary approaches for evidence-based pharmacotherapy.Update on the pharmacotherapy for myelodysplastic syndromes.Darbepoetin alfa for anemia with myelodysplastic syndrome.
P2860
Q24186244-129B757D-18B3-46AD-B355-BAED184C9840Q24202526-FBC94555-31C0-4567-806F-7D5B1D3CA29FQ26866922-7DF92764-48AA-46E6-A7D8-A5EEEC47D4E5Q26866945-76BF3B63-BEFC-4CD7-9B90-5960259C97C7Q27004170-F4C4386A-F5DA-4033-9799-DFBE47BD1561Q27023196-7F8A3A03-04A2-459C-A8E0-83528520871CQ28533886-4400DFE4-B644-4DD7-AABB-458948E2CCC7Q30238892-6D0019CF-9E65-4510-9801-7F0615750C61Q30656245-7174023F-3B04-492A-BA24-50EECF820CBBQ33848929-B1F7278D-AD00-4BDB-B6B1-7B3B474F873BQ33874659-84AA40A0-070E-4922-AD72-8ECB4AC253B6Q33878270-3EE410E4-D214-4407-8D98-66DBD1A1BE2AQ34022950-3C076D00-1DDC-4034-AACA-1212054CC369Q34403952-644B6375-6FEF-4B78-8C38-866061EBFF4EQ34769270-22CB2CD9-57B2-44E4-B680-42F0F2505F82Q34893552-30AB1506-392E-48A5-86F3-B7E6350E297CQ34897067-27756AC4-EA6D-4A24-AD95-E8F2CA7869EEQ35525651-A54A01A1-D1E0-47E1-BEF7-5F09B6AA1094Q35578595-48F4703C-3F50-49A7-B077-EFD811BB5C54Q35583842-A07954DB-8BCA-4844-A98B-3A79B238EC4CQ35692391-EEE8DE95-DD89-4B19-9B0A-02E0BCA8BA71Q36371665-42AC6F56-EEBD-4672-AB3F-367C0C315238Q36551637-439DB90C-C4EB-43ED-BF86-F89526845057Q36603509-7F14D232-29BC-4CCC-AD8E-2A8453B66F25Q36612686-57632696-3F2B-401D-A996-844AE0B88D02Q36931329-7F616C73-05A6-48AD-A6BB-E56A5E851ED2Q37089777-45C054BF-891C-4BDF-AE7C-68088AEFC117Q37129166-A6EE2284-7B6F-411F-996A-7B5D9C25FB23Q37144501-4A8FE579-8066-4703-87B5-A4AD239FEB8DQ37233036-0A3690EB-1818-4262-BEDA-0C74DFC70F14Q37355996-50522451-7141-49BA-BB84-F04E93870579Q37426566-E78A0061-6AA0-43CB-A465-F5A1B234A5AAQ37429231-792E3C52-5DE3-462B-89B5-14531DCA5486Q37868637-D5D91DD7-55A2-4D8C-9250-348C5467C85CQ37880158-2C6A2A0F-5470-413E-95FA-DDA62F9506CCQ37999380-DE9C2644-10F4-4F0A-9D25-CC055B3C42F9Q38057813-78DDF16E-5CEA-4289-9D28-67014283699CQ38086404-A19B4E79-291D-4BBD-9C4E-3133B920D779Q38235662-825A344A-73A2-4C17-AF40-772ECB031BC3Q38314705-5547F94B-6CBC-499E-99E0-78CA5774A881
P2860
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
American Society of Hematology ...... in adult patients with cancer.
@ast
American Society of Hematology ...... in adult patients with cancer.
@en
type
label
American Society of Hematology ...... in adult patients with cancer.
@ast
American Society of Hematology ...... in adult patients with cancer.
@en
prefLabel
American Society of Hematology ...... in adult patients with cancer.
@ast
American Society of Hematology ...... in adult patients with cancer.
@en
P2093
P1433
P1476
American Society of Hematology ...... in adult patients with cancer.
@en
P2093
American Society of Hematology ...... ice Guideline Update Committee
Ann A Jakubowski
Charles L Bennett
David H Regan
J Douglas Rizzo
Jerome Seidenfeld
Jerry L Spivak
Mark R Somerfield
Matthew J Goode
Melissa Brouwers
P304
P356
10.1182/BLOOD-2010-08-300541
P407
P577
2010-10-25T00:00:00Z